Background {#Sec1}
==========

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of childbearing age \[[@CR1]\]. Although the precise prevalence of PCOS in adolescent girls is still unknown, a recent meta-analysis conducted on this age group estimated it to be 3.39 and 11.4% based on the National Institute of Health (NIH) and Rotterdam criteria, respectively \[[@CR2]\]. This syndrome is characterized by ovulation irregularities, clinical with or without biochemical hyperandrogenism, and polycystic ovaries \[[@CR2]\]. In addition to the clinical and hormonal features, this disease is often associated with an increased risk of metabolic disturbances, such as obesity, dyslipidemia, insulin resistance, and type 2 diabetes mellitus, which predispose patients for cardiovascular diseases \[[@CR3]\]. Insulin resistance is prevalent in both lean and obese women with PCOS and is seen in adolescents with hyperandrogenism and in prepubertal girls with early adrenarche \[[@CR4]\]. Although PCOS begins at puberty, the source of ovarian androgen production disorder at puberty originates in childhood or even during fetal development \[[@CR5]\]. The pathological features in adolescence are still debated since most diagnostic criteria, such as menstrual irregularity, hirsutism, acne, and polycystic ovary morphology (PCOM) are common in normal adolescent females and considered physiologic changes of puberty \[[@CR6]\].

Several treatment options are available for managing adolescent girls with PCOS \[[@CR7]\]. Recommended treatments, especially in this age group, should be safe, acceptable, and tolerable \[[@CR8]\]. However, there are no sufficient data available regarding the safety of pharmacological treatments, and especially related to long term usage in young women with PCOS \[[@CR9]\]. Additionally, none of these drugs have been approved so far by the US Food and Drug Administration (FDA) to use in adolescents with PCOS \[[@CR10]\].

Lifestyle modification (LSM) is considered as an effective and safe option and the first line of treatment in adolescent girls \[[@CR11]\]. Lifestyle interventions, which mainly include dietary change and physical activity, can reduce the prevalence of obesity and hormonal disorders in adolescents \[[@CR12]\]. This non-invasive intervention, especially in adolescents, causes 5 to 10% weight loss in obese girls with PCOS \[[@CR13]\], and can decrease androgen levels and menstrual cycle irregularities \[[@CR14]\]. A systematic review has shown that LSM can improve clinical, hormonal, and metabolic parameters of PCOS in young patients \[[@CR6], [@CR15]\].

Despite several existing studies on PCOS in adolescents, a limited number of studies have evaluated the efficacy of treatments of PCOS, in particular LSM in this age group, and have reported conflicting results \[[@CR10], [@CR16]--[@CR19]\]. In addition, to the best of our knowledge, there has been no meta-analysis assessing the effects of LSM on PCOS symptoms in adolescent girls; hence, this study aimed to evaluate the effects of LSM on anthropometric, clinical, and biochemical parameters in adolescent girls with PCOS.

Methods {#Sec2}
=======

The current meta-analysis was designed based on the guidelines for the preferred reporting items for systematic reviews and meta-analyses (PRISMA) \[[@CR20]\]. The PICOT question of the study was: What are the effects of lifestyle modifications on the anthropometric, clinical, and biochemical parameters in adolescent girls with PCOS after 3--12 months of intervention. The study protocol was registered in PROSPERO with CRD42020150812 number.

Search strategy {#Sec3}
---------------

PubMed, Web of Science, Scopus and Cochrane Library was searched to retrieve studies that were published up to December of 2019. The studies were limited to those that focused on investigating lifestyle modifications in adolescent girls with PCOS. Two reviewers (S.A., M.A.) performed searches separately. Keywords used in the search included:

("life style" OR "lifestyle" OR "Life Change Events" OR "weight loss" OR "modification" OR "diet" OR "nutrition" OR "nutritional status" OR "food" OR "energy intake" OR "calorie" OR "exercise" OR "physical activity" OR "fitness" OR "behavior" OR "psychiatry" OR "psychology" OR "stress" OR "anxiety" OR "alcohols" OR "drinking" OR "alcohol drinking" OR "smoking") AND ("polycystic ovarian syndrome" OR "polycystic Ovary Syndrome" OR "PCOS" OR "Stein Leventhal Syndrome") AND ("adolescent" OR "adolescence" OR "teens" OR "teen" OR "teenagers" OR teenager" OR "youth" OR "youths" OR "child").

The search was limited to human studies and English language publications. Search strategies were almost the same for all databases, which were conducted based on the 'all fields' in the PubMed and 'titles, abstracts, and keywords' in other databases. We also appraised the reference lists of all included studies for any additional publications that could be used in this review.

Eligibility criteria {#Sec4}
--------------------

All clinical trials published in the English language, without any time limitation that investigated lifestyle interventions/modifications in a study population of adolescent girls with PCOS were included in the study. Non-clinical trial studies that evaluated an adult population, did not mention diagnostic PCOS criteria, used drug interventions in combination with lifestyle interventions, or those with unreliable and incomplete results were omitted from the study. The intervention of interest was lifestyle modification/interventions, including nutrition interventions (diet therapy or nutrition intervention including nutrition education or nutrition/dietary consulting at schools, or medical centers), physical activity interventions (exercise or fitness or yoga) and behavior interventions.

Outcome measure {#Sec5}
---------------

The primary outcome was Body Mass Index (BMI) and the secondary outcomes were all manifestations of PCOS, including clinical \[FG score, menstrual cycles, BMI and Blood Pressure (BP)\], metabolic parameters \[Fasting Blood Sugar (FBS), Fasting Blood Insulin (FBI), Homeostatic Model Assessment - Insulin Resistance (HOMA-IR), Triglyceride (TG), Low-Density Lipoprotein (LDL), High-density Lipoprotein (HDL)\], and hormonal parameters \[Sex Hormone Binding Globulin (SHBG), Follicle-Stimulating Hormone (FSH), LH, Total Testosterone (TT), and Bioavailable Testosterone (BT), AFI, AMH\].

Study selection {#Sec6}
---------------

All relevant clinical trials investigating the effect of lifestyle modification/interventions on PCOS manifestations in adolescent girls with PCOS were included. At least one of the following outcomes had to be reported: hirsutism, menstrual cycles, and androgenic, metabolic parameters such as FBS, FBI, HOMA-IR, TG, TC, LDL, HDL, anthropometric parameters, and blood pressure. After initial screening by one reviewer (SA), the potentially eligible studies were entered into the software Endnote. The first selection was performed based on their titles, followed by a second selection performed by one reviewer who deleted duplicates and reviewed the abstracts of all remaining records. If there was any difference of opinions in the selection of abstracts, it was resolved by consensus or by another reviewer. Full-text papers of all selected abstracts were obtained for reviewing and data processing.

Data extraction {#Sec7}
---------------

For minimizing errors, two reviewers (S.A. and M.A.), in close consultation with senior reviewers, extracted data from full-text articles and double-checked all data extracted to minimize errors. The following data were extracted (if available): author, publication year, country, methodology, including criteria for sample size, study design, time of intervention, duration of intervention, and main outcomes. Any disagreement was settled by discussion or, if required, consultation with a third person and via the consensus strategy. We documented the selection process in sufficient detail to complete a PRISMA flow diagram.

Quality assessment {#Sec8}
------------------

The two reviewers (S.A. and M.A.) who were blinded to the study author, institution, journal name, volume, and page, assessed the quality of each study separately. Any dispute was resolved and adjusted by the senior reviewer (F.R.T.). The most important items of the Modified Consolidated Standards of Reporting Trials (CONSORT) checklist were used to assess the quality of RCTs \[[@CR21]\]. In this respect, the quality of RCTs was individually evaluated using predefined criteria. High-quality studies were defined as total score \> 60%, fair quality (40--60% score), and poor quality (\< 40% score) (Table [1](#MOESM1){ref-type="media"} in Additional file [1](#MOESM1){ref-type="media"}).

Risk of bias assessment {#Sec9}
-----------------------

The two authors (S.A. and M.A.) independently assessed the risk of bias in each study included using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions \[[@CR22]\]. Seven domains related to the risk of bias were assessed in each RCT: (1) random sequence generation, (2) allocation concealment, (3) blinding of outcome assessment, (4) comparison with control group, (5) incomplete outcome data, (6) selective outcome reporting, and (7) comparison with baseline. Review authors' conclusions were considered as 'low risk', 'high risk' and 'unclear risk' of bias (Table [2](#MOESM1){ref-type="media"} in Additional file [1](#MOESM1){ref-type="media"}).

Statistical analysis {#Sec10}
--------------------

This meta-analysis was conducted to obtain the pooled standardized mean difference of clinical features (BMI, menstrual cycle, and FG), blood pressure (SBP and DBP), and lipid profiles (TG, HDL, and LDL), glucose metabolism (FBS, FBI, and HOMA-IR), hormone profiles (FSH, LH, AMH, SHBG, FT, BT, TT, and AFI).

Means and SDs of data at baseline and after treatment were collected. For effect measures, the mean difference (MD) and related 95% confidence intervals (CIs) were calculated based on means of pre-treatment and those at end of treatment levels.

Forest plots summarize the mean difference (CI 95%) by using variance between studies and the random effect model. I-squared statistics were estimated as the measures of heterogeneity. Random effect meta-analysis was applied for significant results (I2 greater than 50% or the Chi-squared test), otherwise the fixed-effect model was applied. Publication bias was assessed using the Egger test \[[@CR23]\]. Meta-regression analyses were also conducted to adjust lifestyle intervention types and follow-up time as a confounding variable.

Results {#Sec11}
=======

Search results, study selection, study characteristics, and quality assessment {#Sec12}
------------------------------------------------------------------------------

A flow chart of the literature search and its results are shown in Fig. [1](#Fig1){ref-type="fig"}. We screened a total of 1777 records from the following databases: Web of Science (366), PubMed (188), and Scopus (1224). Finally, eleven studies were included in the meta-analysis; of these, five studies were classified as having high quality, four studies as fair, and two as low quality (Table [1](#MOESM1){ref-type="media"} in the supplementary file). Therefore, most studies included in the meta-analysis had moderate quality. The study population consisted of 412 adolescent girls with PCOS in 16 interventions and 3 control groups. Five studies with lifestyle interventions (the combination of dietary, physical activity, and behavior habits intervention) \[[@CR24]--[@CR28]\], four studies with dietary interventions \[[@CR29]--[@CR32]\], and two studies with exercise interventions were entered in this study \[[@CR33], [@CR34]\]. The characteristics of these studies are shown in Table [1](#Tab1){ref-type="table"}. Fig. 1PRISMA flow diagram of study selectionTable 1Characteristics of studies includedAuthor (year)\
settingStudy designSample sizeGroups\
(mean age and bmi)PCOS diagnosis criteriaLife style modificationFollow up durationoutcomeMain resultWong et al.,2016USARCT19Group 1: patient with diet intervention and Weight loss *n* = 9Mean age:16.3 ± 2.2Mean BMI baseline: 32.80 ± 3.20Mean BMI after:30.9 ± 3.70Group 2: patient with diet intervention and non-Weight loss *n* = 10Mean age:15.4 ± 1.3Mean BMI baseline:36.50 ± 4.30Mean BMI after:36.10 ± 4.70Androgen Excess SocietyDietLGL (45% carbohydrate, 35% fat, 20% protein) or LF (55% carbohydrate, 25% fat, 20% protein) diet6 monthsBMI, BP,FBSFBI,SHBG,TGHDL, LDL,TTFT, BT↓BMILass et al.,2011GermanNRS59Group 1: patient with lifestyle intervention and Weight loss *n* = 26Mean age:14.9 ± 0.8Mean BMI baseline:32.20 ± 3.70Mean BMI after:28.30 ± 3.40Group 2: patient with lifestyle intervention and non-Weight loss *n* = 33Mean age:15.1 ± 0.7Mean BMI baseline:33.90 ± 6.8Mean BMI after:34.60 ± 6.90National Institutes of HealthDiet30% fat, 15% proteins, and 55% carbohydrates including 5%sugarExercisedancing, ball games, jogging, trampoline jumpingBehavior12 monthsBMI, BP,FBSFBI, SHBGHOMA, TGHDL, LDL, FSHLH, FT, AFI↓BMI, ↓TG, ↓HOMA, ↓testosterone, ↓FAI, ↓LH, ↓systole and ↓diastole blood pressureReinehr et al., 2017GermanNRS20Group 1: patient with lifestyle intervention and Weight loss *n* = 10Mean age:: 14.9 ± 1.4Mean BMI baseline:32.20 ± 4.10Mean BMI after: 27.40 ± 2.5Group 2: patient with lifestyle intervention and non-Weight loss *n* = 10Mean age:15 ± 1.2Mean BMI baseline:31.40 ± 4.90Mean BMI after:33.30 ± 6.6Endocrine Society proposedDiet30% fat, 15% proteins, and 55% carbohydrates including 5%sugarExercisedancing, ball games, jogging, trampoline jumpingBehavior12 monthsBMI, SHBGHOMA, FSHLH, FT, AFIAMH↓BMI, ↓LH, ↑SHBG, ↓FAI, ↓HOMA, ↓AMHHoeger et al.,2008USARCT18Group 1: patient with lifestyle intervention *n* = 8Mean age: 15.4 ± 1.2Mean BMI baseline:36 ± 6.20Mean BMI after: 34.90 ± 7Group 2: patient with no intervention (control) *n* = 10Mean age: 15.4 ± 1.7Mean BMI baseline:34.90 ± 6.7Mean BMI after: 34.90 ± 6.70Rotterdam criterionDietHypo caroric diet with 500 kcal/d deficitExercise:30 min/d ofmoderate to intense activity6 monthsBMI, BP,FBSFBI, TG, SHBGHDL, LDL, TTAFI, FG↓FAI, ↑SHBG, ↓Diastolic blood pressureOrnestein et al.,2011ChicagoRCT16Group 1: patient with diet intervention*n* = 16Mean age: 15.8 ± 2.2Mean BMI baseline: 35.70 ± 6Mean BMI after: 32.90 ± 5.80Rotterdam criterionDiet:Low fatless than 40 g per day of fat, with five servingsof starch per day and an ad libitum intake of fat-free dairyfoods, fruits, vegetableslow carbohydrate:40 g carbohydratedaily by adding low glycemic index foods, such as nuts, fruits,And whole grains.3 monthsBMI↓BMILadson et al.,2011USARCT11Group 1: patient with lifestyle intervention *n* = 11Mean age: 15.4 ± 1.2Mean BMI baseline: no reportedMean BMI after: no reporteNational Institutes of HealthDiet:55% carbohydrate, 30% fat, and15% protein.Exercise: 35--45 stair stepper, stationarybike, elliptical machine, treadmill, or dancing to music6 monthsBP, FBS, FBIHOMA, TGSHBG, HDLLDL, FSHLH, BT,AFINo significant difference in all of measurement outcomeNidhi et al.,India2012RCT71Group 1: patient with yoga intervention*n* = 42Mean age:16.22 ± 1.13Mean BMI baseline:20.22 ± 1.65Mean BMI after:20.11 ± 1.70Group 2: patient with exercise intervention *n* = 43Mean age:16.22 ± 0.93Mean BMI baseline:21.28 ± 3.05Mean BMI after: 21.59 ± 2.78Rotterdam criterionExercise:A yogasuryanamaskara, asanas, pranayama, and meditation3 monthsBMI, FBS,FBIHOMA, TGHDL, LDL↓FBS, ↓HOMA, ↓TG, ↓LDLNidhi et al.,India2013RCT72Group 1: patient with lifestyle intervention *n* = 45Mean age: 16.22 ± 1.13Mean BMI baseline:20.39 ± 2.60Mean BMI after:20.41 ± 2Group 2: patient with no intervention (control) *n* = 45Mean age:16.22 ± 0.93Mean BMI baseline:21.39 ± 3.20Mean BMI after:21.70 ± 2.88Rotterdam criterionExercise:A yogasuryanamaskara, asanas, pranayama, and meditation3 monthsBMI, FSH, LHTT, AMH, FGmenstrual period↓TT, ↓LH, ↓AMH, ↓FG,menstural period improveCarolo et al.,2017BrazilNRS18Group 1: patient with lifestyle intervention and Weight loss n = 9Mean age:16.56 ± 1.33Mean BMI baseline:88.10 ± 13.3Mean BMI after:81.40 ± 11.20Group 2: patient with diet intervention and non-Weight loss *n* = 9Mean age:16 ± 1.66Mean BMI baseline:78.70 ± 17.30Mean BMI after:84.8 ± 20.7Endocrine SocietyDiet55--75% of carbohydrate, 10--15% ofProtein and 15--30% of total fat.6 monthsBMIDietary interventions were not beneficial for BMI improve.Rofey et al.,2009USANRS12Group 1: patient with lifestyle intervention *n* = 12Mean age: 15.8Mean BMI baseline:39 ± 9Mean BMI after:35 ± 6National Institutes of HealthBehavior:cognitive--behavioral therapy (CBT)Exercise:(yoga instructor, local swim coach, climbing wall supervisor)3 monthsBMI↓ BMI.Marzouk et al.,2015EgyptRCT60Group 1: patient with diet intervention*n* = 30Mean age:19.3 ± 1.3Mean BMI baseline:36.4 ± 4.7Mean BMI after:33.20 ± 3.8Group 2: patient with no intervention (control)*n* = 30Mean age:20.1 ± 1.8Mean BMI baseline:35.8 ± 4.8Mean BMI after:35.7 ± 4.67Rotterdam criterionDiet15--20% of protein, 30%of fat, 50--55% of carbohydrates6 monthsBMI, FGmenstrual period↓ BMI, ↓FG, menstrual period improve.*PCOS* polycystic ovarian syndrome; *BMI* body mass index; *FSH* Follicle-stimulating hormone; *LH* Luteinizing Hormone; *FBS* fasting blood sugar; *HOMA* Homeostatic model assessment; *FBI* Fasting blood index; *TG* Triglyceride; *LDL* Low-density lipoprotein; *HDL* High-density lipoprotein; *SHBG* Sex Hormone Binding Globulin; *TT* total testosterone; *FT* free testosterone; *BT* bioavailable testosterone; *FAI* free androgen index; *AMH* Anti-Müllerian hormone; *BP* Blood pressure; *FG* Ferriman-Gallwey; *LF* Low Fat; *LGL* Low Glycemic Load

Three studies were excluded because of having incomplete outcome data \[[@CR35]\], repetitive data \[[@CR36]\], and one being a longitudinal design study \[[@CR37]\].

The results for risk of bias are shown in Table [2](#MOESM1){ref-type="media"} in the supplementary file. For random sequence generation, seven trials (7 out of 11, 63%) were deemed to be at low risk \[[@CR26], [@CR29]--[@CR31], [@CR33], [@CR34], [@CR38]\], and for allocation concealment, seven trials were at unclear risk (7 out of 11, 63%) \[[@CR25], [@CR27], [@CR29], [@CR31], [@CR33], [@CR34], [@CR38]\]. In three trials (3 out of 11, 27%), the participants or providers, or both, were blinded to treatment allocation \[[@CR24], [@CR33], [@CR34]\]. Eight trials (8 out of 11, 72%) reported attrition bias \[[@CR25]--[@CR27]\]. All of the included studies were deemed to be at low risk for comparing before-after intervention results and for selecting outcome reports. The intervention and control groups were demonstrably comparable in six trials (6 out of 11, 55%) \[[@CR30], [@CR33], [@CR34], [@CR38], [@CR39]\] \[[@CR26], [@CR27]\]. Some biases were more probable such as blinding of outcome assessment and allocation concealment.

Meta-analysis of outcomes {#Sec13}
-------------------------

A summary of the key findings reported in each of the outcomes assessed in this meta-analysis is presented in Table [2](#Tab2){ref-type="table"}. Pooled SMD (95% CI) in treatment groups is shown in these tables. Table 2Results of meta-analysisi and Meta-regressionOutcomesN^a^I^2^%^c^Publication biasPooled SMD (95%CI)^b^Meta-regression coefficient\
(*P*-Value)SMDLCIUCIBMI*Intervention: lifestyle*469.90.088−0.442− 0.9860.102− 0.47 (0.119)*Intervention: Exercise*20.00.1250.017−0.2260.260−0.038 (0.896)*Intervention: Diet*40.00.147−0.450−0.760− 0.139− 0.47 (0.128)*Control*30.00.5680.057−0.2420.356ReferenceFG score1*Intervention: lifestyle*----−0.509−1.3600.341−0.57 (0.344)*Intervention: Exercise*1----−0.575− 0.996−0.153− 0.63 (0.139)*Intervention: Diet*1----− 0.807− 1.334−0.280− 0.86 (0.108)*Control*3----0.056− 0.2430.355ReferenceSBP*Intervention: lifestyle*272.20.602− 0.070−0.7430.602− 0.335 (0.651)*Intervention: Exercise*0------------*Intervention: Diet*10--0.267− 0.3720.9070 .014 (0.986)*Control*1----0.252− 0.5881.091ReferenceDBP*Intervention: lifestyle*268.80.117−0.216− 0.8550.4220.135 (0.861)*Intervention: Exercise*0------------*Intervention: Diet*100.317−0.451− 1.0930.191−0.081 (0.905)*Control*1----− 0.349− 1.1920.494ReferenceMenstrual cycle*Intervention: lifestyle*0----------NA*Intervention: Exercise*1----1.1650.7181.613NA*Intervention: Diet*1----0.467− 0.0460.980NA*Control*2530.3170.344− 0.1380.826NAFBS*Intervention: lifestyle*20--0.113−0.2190.4450.246 (0.746)*Intervention: Exercise*1940.317−0.530− 1.8080.748− 0.374 (0.636)*Intervention: Diet*1----− 0.092− 0.7290.5450.052 (0.950)*Control*1----− 0.148− 0.9850.689ReferenceFBI*Intervention: lifestyle*278.30.117−0.066−0.8240.693−0.192 (0.814)*Intervention: Exercise*185.10.317−0.126−0.9140.661− 0.444 (0.779)*Intervention: Diet*10--− 0.108−0.7490.533−0.234 (0.758)*Control*1----0.126− 0.7110.962ReferenceHOMA-IR*Intervention: lifestyle*200.2540.000− 0.3120.312--*Intervention: Exercise*100.3170.000−0.3010.301--*Intervention: Diet*0------------*Control*0------------TG*Intervention: lifestyle*264.10.317−0.097− 0.7050.511− 0.095 (0.235)*Intervention: Exercise*100.317−0.321− 0.624−0.018− 0.180 (0.584)*Intervention: Diet*100.117−0.097−0.7050.511−0.041 (0.784)*Control*1----−0.236−1.0750.603ReferenceSHBG*Intervention: lifestyle*370.10.4210.593−0.0041.1910.341 (0.623)*Intervention: Exercise*0------------*Intervention: Diet*100.1170.007− 0.6300.644− 0.224 (0.784)*Control*1----0.235− 0.6041.074ReferenceHDL*Intervention: lifestyle*235.50.2170.317− 0.1150.749−0.075 (0.879)*Intervention: Exercise*100.1170.089−0.2120.389−0.311 (0.532)*Intervention: Diet*100.1170.056−0.5820.694−0.343 (0.560)*Control*1----0.400− 0.4451.245ReferenceLDL*Intervention: lifestyle*200.317−0.059− 0.3900.2730.063 (0.898)*Intervention: Exercise*154.1%0.117−0.431− 0.8820.021−0.301 (0.542)*Intervention: Diet*100.117−0.455− 1.1000.190−0.333 (0.571)*Control*1----−0.122− 0.9580.715ReferenceFSH*Intervention: lifestyle*228.20.2540.049−0.3370.4350.202 (0.635)*Intervention: Exercise*00--− 0.207−0.6210.207−0.063 (0.900)*Intervention: Diet*0------------*Control*1----− 0.144−0.5580.270ReferenceLH*Intervention: lifestyle*228.20.254−1.235−2.440− 0.030−2.115 (0.564)*Intervention: Exercise*00--− 0.561−0.982− 0.140−0.982 (0.894)*Intervention: Diet*0------------*Control*1----0.4200.0030.838ReferenceTT*Intervention: lifestyle*1----0.140−0.6970.977−0.0476 (0.952)*Intervention: Exercise*1----−0.288− 0.7030.128− 0.476 (0.236)*Intervention: Diet*100.117−0.050− 0.6860.586−0.238 (0.592)*Control*100.1170.188−0.1830.559Reference FT280.2*Intervention: lifestyle*0.542−0.486− 1.2770.306--*Intervention: Exercise*0------------*Intervention: Diet*1810.117−1.042− 2.7370.653--*Control*0----------ReferenceBT*Intervention: lifestyle*0------------*Intervention: Exercise*0------------*Intervention: Diet*10--−0.073−0.7100.564--*Control*0----------ReferenceAFI*Intervention: lifestyle*373.80.452−0.778− 1.425−0.131− 0.918 (0.400)*Intervention: Exercise*0------------*Intervention: Diet*0------------*Control*10--0.119−0.7180.955ReferenceAMH*Intervention: lifestyle*187.20.117−1.230−3.2590.798−1.084 (0.654)*Intervention: Exercise*1----−0.809− 1.239−0.378−0.622 (0.541)*Intervention: Diet*0------------*Control*1----− 0.187−0.6010.227Reference^a^Heterogeneity Index: Value upper 50% needs Random effect method of estimation^b^Meta-regression coefficient showed difference of intervention vs. control^c^Egger test of publication bias which test small-study effects

Body mass index {#Sec14}
---------------

Ten studies reported the effect of lifestyle on BMI, four studies evaluated diet \[[@CR29]--[@CR32]\], two studies evaluated exercise \[[@CR33], [@CR34]\] and four studies used a combination of these interventions \[[@CR25]--[@CR28]\].

Our results showed that only diet intervention was associated with a significant decrease in BMI (Pooled SMD = − 0.45; 95% CI, − 0.76 to − 0.14) (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Forest plot of pooled mean difference standardized of BMI

Clinical parameters {#Sec15}
-------------------

In general, six studies reported the effect of LSM on clinical parameters including menstrual cycles, FG, and systolic and diastolic blood pressure; two of these studies assessed the effect of diet \[[@CR29], [@CR30]\], one study evaluated exercise \[[@CR33]\], and three studies assessed the combination of diet, exercise, and behavior \[[@CR24]--[@CR26]\].

Results showed that exercise intervention significantly improved menstrual cycle regularities (Pooled SMD = 1.16; 95% CI, − 0.72 to 1.61) and the FG score (Pooled SMD = − 0.57; 95% CI, − 0.99 to − 0.15). In addition, diet therapy was associated with a significant decrease in FG scores (Pooled SMD = − 0.81; 95% CI, − 1.33 to − 0.28) (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Forest plot of pooled mean difference standardized of menstrual cycle and FG score

Lifestyle intervention had no significant effect on systolic or and diastolic blood pressure (Fig. [1](#MOESM1){ref-type="media"} in Additional file [1](#MOESM1){ref-type="media"}).

Metabolic parameters {#Sec16}
--------------------

In general, six studies reported on the effect of one lifestyle intervention type on metabolic parameters including TG, HDL, LDL, FBS, FBI, and HOMA-IR. Another study evaluated the effect of diet \[[@CR29]\], one study evaluated the effect of exercise \[[@CR34]\], and four studies evaluated the effect of a combination of diet, exercise, and behavior modification \[[@CR24]--[@CR27]\].

Results revealed that exercise intervention significantly decreased the TG level (Pooled SMD = − 0.32; 95% CI, − 0.62 to − 0.02) (Fig. [4](#Fig4){ref-type="fig"}). This study showed that lifestyle interventions (diet, exercise, and behavior) had no significant effects on HDL, LDL, FBS, FBI, and HOMA-IR (Figs. [2](#MOESM1){ref-type="media"}, [3](#MOESM1){ref-type="media"}, [4](#MOESM1){ref-type="media"} in Additional file [1](#MOESM1){ref-type="media"}). Fig. 4Forest plot of pooled mean difference standardized OF TG

Hormonal parameters {#Sec17}
-------------------

In general, six studies reported the effect of LSM on metabolic parameters, including FSH, LH, SHBG, TT, FT, BT, FAI, and AMH. One of these studies evaluated the effect of diet \[[@CR29]\], one study evaluated the effect of exercise \[[@CR33]\], four studies evaluated effects of the combination of these interventions \[[@CR24]--[@CR27]\].

Meta-analysis results showed that LSM (combination of diet, exercise, and behavior intervention) was significantly associated with a decrease in LH (Pooled SMD = − 0.1.2; 95% CI, − 2.44 to − 0.03), and FAI (Pooled SMD = − 0.78 95% CI, − 0.1.42 to − 0.13). In addition, the exercise intervention significantly decreased LH (Pooled SMD = − 06; 95% CI, − 0.98 to − 0.14) and AMH levels (Pooled SMD = − 0.81; 95% CI, − 0.1.24 to − 0.38) (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Forest plot of pooled mean difference standardized of hormonal parameters

LSM had no significant effects on other hormonal parameters, including FSH, SHBG, TT, FT, BT levels (Figs. [5](#MOESM1){ref-type="media"}, [6](#MOESM1){ref-type="media"} in Additional file [1](#MOESM1){ref-type="media"}).

Meta-regression analysis {#Sec18}
------------------------

The results of meta-regression showed differences in the clinical, hormonal, and metabolic parameters between interventions and control groups. Our univariate meta-regression analysis found no significant effects between lifestyle intervention types compared to the control group (Table [2](#Tab2){ref-type="table"}). In addition, the results of meta-regression adjusted for duration of follow-up showed no significant effects of this confounder (Table [3](#Tab3){ref-type="table"}). Table 3Results of effect of follow-up time in Meta-regression analysisOutcomes^a^Meta-regression coefficient(***P***-Value)**BMI**−.005669 (0.911)**FG score**.0198017 (0.878)**SBP**−.1612566 (0.245)**DBP**.1273615 (0.353)**Menstrual cycle**@**FBS**.010024 (0.945)**fasting blood insulin**.0809897 (0.596)**HOMA-IR**@**TG**−.0863414 (0.439)**SHBG**.0365641 (0.785)**HDL**.0754495 (0.403)**LDL**.0311606 (0.720)**FSH**.0223895 (0.639)**LH**−.2349961 (0.564)**TT**.0136399 (0.944)**FT**@**BT**@**AFI**.0597252 (0.778)**AMHr**@^a^Meta-regression coefficient showed difference of intervention vs. control@ insufficient data

Publication Bias {#Sec19}
----------------

The results of the Egger test showed no significant publication bias for clinical, metabolic, and hormonal variables.

Discussion {#Sec20}
==========

This study compared the effects of LSM on anthropometric, clinical, and biochemical parameters in adolescent girls with PCOS. In this meta-analysis that included 11 studies involving 412 adolescent girls, we observed that LSM, especially exercise was significantly associated with an improvement in some clinical, metabolic and hormonal findings of PCOS in this population.

In general, the main lifestyle interventions recommended for adolescents with PCOS include exercise, diet, and behavior habit modifications. It has been suggested that lifestyle modification (LSM) can improve menstrual cycle disorders, insulin resistance, and hyperandrogenism through reducing energy intake and weight management \[[@CR40], [@CR41]\].

In line with the mentioned mechanisms, the result of our study demonstrated that LSM for 3 to 12 months can significantly decrease the levels of LH and FAI, although we did not observe any changes in other hormonal parameters (FSH, TT, SHBG, and FT, BT, and AMH). We also found that LSM can significantly decline TG levels, whereas it did not affect the levels of other metabolic parameters.

Previous studies on PCOS patients reported that LSM is associated with an increase in spontaneous pregnancy through the restoration of ovulatory cycles \[[@CR42], [@CR43]\]. A Cochrane review on 15 studies with 498 participants suggested that LSM can improve body composition in women with PCOS \[[@CR44]\], which is similar to our findings. On the contrary, a meta-analysis of 12 RCTs demonstrated that LSM alone for 6 months cannot improve reproductive outcomes (menstrual irregularity, and hirsutism), and metabolic features \[[@CR45]\]. This discrepancy might be related to differences in studied populations (adult women vs. adolescents), duration of intervention, and type of lifestyle interventions.

Most included studies in the meta-analysis evaluated the impact of exercise and diet therapy as LSM \[[@CR24], [@CR25], [@CR29], [@CR34]\]. There is evidence demonstrating that exercise is associated with significant improvements in ovarian morphology, and ovulatory cycles, mainly through decreasing plasma TNF-α, and increasing plasma IL-4 and IL-10. In addition, it is well-documented that decreased insulin concentration during intensive exercises can improve hirsutism, acne, and menstrual regularity \[[@CR46]\].

The present study showed that exercise intervention (yoga) was associated with a significant improvement in clinical manifestations of PCOS, including the FG score, and menstrual cycle irregularity. In addition, exercise significantly diminished serum levels of LH, FAI, and AMH. Moreover, this study showed significant improvement in TG levels after intervention with exercise, whereas there were no changes in the levels of other metabolic parameters with this intervention. Yoga is an alternative exercise activity that might be effective in improving anxiety and mood of adolescence \[[@CR47]\], and ovarian morphology in PCOS adult women \[[@CR48]\].

Similar to our findings, two other studies showed that weight reduction, through increasing physical exercise alone, can be effective in regulating menstrual cycles \[[@CR11], [@CR49]\]. Some studies demonstrated that in addition to physical activity, eating habits and stressful lifestyles have direct effects on the menstrual regularity in adolescent girls \[[@CR50]--[@CR52]\] and adult women \[[@CR53]\]. In agreement with our results, a meta-analysis of 27 studies of adult women with PCOS has shown beneficial effects of exercise alone in terms of metabolic factors and anthropometric outcomes \[[@CR54]\]. In addition, another meta-analysis of 14 studies involving 617 adult women with PCOS found that exercise improved lipid profiles and decreased waist circumference, systolic blood pressure and fasting insulin, whereas the impact of exercise interventions on reproductive function remained unclear \[[@CR55]\].

Evidence suggests that environmental factors such as dietary habits play an important role in the prevention and treatment of PCOS \[[@CR56]\]. Indeed, dietary modifications alone, either through qualitative changes or caloric restriction, may improve insulin resistance and hyperandrogenism in PCOS patients \[[@CR56], [@CR57]\]. Also, a 5% weight loss through low-calorie diets can improve reproductive system dysfunctions, and fertility in these women \[[@CR2]\]. Data for effects of diet therapy alone on clinical and biochemical parameters of PCOS were limited, but general diet therapy (hypocaloric diet with Low Fat: LF or Low-Glycemic-Load: LGL intervention) was associated with a significant decrease in the BMI, and FG score, whereas this intervention had no significant effects on menstrual cycles, and hormonal and metabolic parameters. One meta-analysis of eight studies in PCOS adult women recommended a hypocaloric diet for the reduction of BMI, treatment of PCOS with insulin resistance, prevention of high LDL-C, increasing the levels of FSH and SHBG, and decreasing the level of TG level \[[@CR58]\].

In this study, LSM was not significantly associated with changes in glucose metabolism, whereas other meta-analyses reported that LSM in adult PCOS women reduced fasting blood glucose, insulin levels and insulin resistance \[[@CR15], [@CR59]\]. We would like to note that intensive lifestyle modification and weight reduction are necessary to reduce circulating insulin and androgen levels \[[@CR46]\] and this conflict might be due to the fact that intensive LSM in adolescents might not be a common phenomenon. Indeed, it has been proposed that weight management with LSM interventions may be less effective in adolescent girls with PCOS. This might be related to the hormonal changes of PCOS such as hyperandrogenemia or insulin resistance, contributing to abnormalities in energy homeostasis and dietary intake including gastrointestinal hormone regulation or a modified metabolism because of reduced thermogenesis following meals \[[@CR60]\]. Moreover, it was stated that the intensity of hyperinsulinemia and insulin resistance (which has a great effect on the phenotype of PCOS) is further influenced by both genetic factors (such as polymorphism in the insulin gene regulatory region) and environmental factors, especially obesity. Therefore, the efficacy of LSM on insulin resistance might be affected by study populations \[[@CR61]\].

In this study, serum levels of lipids showed no significant changes with LSM intervention except in TG level, and the findings were similar to those of other studies in PCOS adults \[[@CR15], [@CR44], [@CR59], [@CR62]\]. We observed that LSM was less effective in glucose metabolism in adolescent girls with PCOS.

The present study did not show a significant effect of LSM on the values of SBP and DBP. Similarly, a meta-analysis on adult women with PCOS found no effect of LSM on blood pressure \[[@CR54]\], although systematic review studies in hypertension women demonstrated that LSM had significant effects on reducing blood pressure in PCOS \[[@CR63]\] and non-PCOS women \[[@CR64], [@CR65]\]. This disagreement could be due to differences in the type and duration of interventions and populations studied \[[@CR63]\].

It must be noted that there is no strong evidence on the type, duration, and intensity of these interventions to improve clinical and biochemical manifestations of this syndrome in adolescent girls. However, some guidelines have recommended that physical activity of longer duration, higher frequency, and intensity result in better maintenance of health. Importantly, moderate to vigorous daily physical activity for at least 60 min is related to better physical and psychosocial health in children and adolescents \[[@CR66]\]. Although the low-glycemic diet in PCOS is recommended \[[@CR46]\], international guidelines have demonstrated that there is limited evidence as to which specific energy equivalent diet type is better \[[@CR67]\]. In addition, based on the international guidelines, a duration of 6 to 12 months is the minimum time for the effects of LSM to show. Moreover, guidelines recommend synchronous use of diet, exercise and psychology changes \[[@CR67]\].

The main strength of this review was its novelty as the first meta-analysis assessing the effect of lifestyle on PCOS adolescents. In addition, in this study, potential confounders, including age, and diagnostic criteria were adjusted and subgroup analysis was performed based on the type of lifestyle intervention.

Our study had some limitations that should be considered in order to interpret the results. The main limitation of this study was the small number of publications assessing the impact of lifestyle modifications in adolescent girls with PCOS, and hence; we were unable to conduct subgroup analysis based on all interventions and outcomes of interest. Also, we could not assess type and intensity of the interventions for exercise and diet therapy due to insufficient data. Although, because of insufficient data, we could not conduct a subgroup analysis based on the follow-up duration, results of our meta-regression showed no significant effect of this confounder. In most studies included in our analysis, LH levels were evaluated in the follicular phase of the menstrual cycle except in participants with oligo or amenorrhea. Due to this problem, lower LH levels after LSM in our results might not be extended to all PCOS adolescents. It should be kept in mind that during adolescence, height is not stabilized, which could affect BMI measurements. There was significant heterogeneity in most outcomes where random effect analysis was done to deal with this heterogeneity. These heterogeneities might be related to clinical heterogeneity, which can be due to variability in PCOS diagnostic criteria and laboratory tests, and study population (e.g., age, BMI, ethnicity or race).

Conclusion {#Sec21}
==========

Our analysis suggests that, although lifestyle modification through reduced calorie intake and regular physical activity can improve clinical, metabolic, and hormonal parameters in adolescent girls with PCOS, further well-designed studies are still required to elucidate and confirm these findings.
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PCOS

:   Polycystic Ovarian Syndrome

BMI

:   Body Mass Index

FSH

:   Follicle-Stimulating Hormone

LH

:   Luteinizing Hormone

FBS

:   Fasting Blood Sugar

HOMA

:   Homeostatic Model Assessment

FBI

:   Fasting Blood Index

TG

:   Triglyceride

LDL

:   Low-density lipoprotein

HDL

:   High-density lipoprotein

SHBG

:   Sex Hormone Binding Globulin

TT

:   Total Testosterone

FT

:   Free Testosterone

BT

:   Bioavailable Testosterone

FAI

:   Free Androgen Index

AMH

:   Anti-Müllerian Hormone

BP

:   Blood Pressure

FG

:   Ferriman-Gallwey

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
=========================

**Supplementary information** accompanies this paper at 10.1186/s12902-020-00552-1.

This article is part of PhD thesis in midwifery and reproductive health department and the Research Institute for endocrine science of Shahid Beheshti University of Medical Sciences.

S.A, F.R.T, and M. A were involved in study design, search in databases, quality assessment, study selection, data extraction, data analysis, manuscript drafting, critical discussion, and revising manuscript. R. B and H.A.M contributed to statistical analysis, interpreting data, critical discussion, and revising manuscript. F. N, D.GH, and M. J contributed to critical discussion and manuscript drafting. All authors read and approved the final manuscript.

No funding was received.

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

The study was approved by the Ethics and Research Committee of Shahid Beheshti University of Medical Sciences (reference number: IR.SBMU.PHNM.1397.100).

The informed consents was not applicable.

Not Applicable.

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.
